February 2026 Research Update

What changed this month

This month added a clearer, longer-term comparison suggesting that people with Bardet-Biedl syndrome (BBS) who received setmelanotide tended to have more weight-related improvement over 52 weeks than similar people receiving usual care. [1]

The comparison linked a phase 3 setmelanotide trial to an outside natural history group from the CRIBBS registry, aiming to make the groups more comparable using statistical matching. In both children and adults, the setmelanotide group had a higher responder rate at 52 weeks and larger average decreases in BMI or body weight than the registry group. [1]

Because this was not a head-to-head randomized trial, the results still leave some uncertainty about how much of the difference is due to the medication versus differences between the trial and real-world care. Even so, this analysis strengthens the overall picture that setmelanotide can be linked with meaningful weight-related changes over about a year when compared with an external usual-care group. [1]

What this may mean for patients and caregivers

For families following research on setmelanotide (a medicine that targets a brain pathway involved in appetite and weight), this study adds a practical comparison: outcomes in treated trial participants were contrasted with outcomes in a registry of people receiving usual care. This may matter now because it helps put 1-year trial results into a more real-world context, but it does not remove all uncertainty because the groups were not assigned by randomization. [1]

What remains unclear is how closely the registry group matched the trial group in day-to-day factors such as other weight-related supports and differences in follow-up. The study also could not compare hunger or quality-of-life measures across the two data sources, so it focuses mainly on weight-related outcomes. [1]

What changed this month

This month added new genetic clues about BBS and a clearer story of how certain gene changes might disrupt the cell structures involved in BBS. Together, the studies support the idea that different BBS gene variants can affect how the BBSome (a group of proteins needed for normal cilia function) is built or stabilized, which may help explain why symptoms can vary across people and families. [2] [3]

In one family study, researchers identified a previously unreported TTC8 change that introduces an early stop signal, predicted to shorten the TTC8 protein and disrupt parts important for binding to other BBSome proteins. Computer-based modeling suggested this could alter how TTC8 interacts with BBS9, offering a specific hypothesis for how the variant could lead to BBS. [2]

In a separate laboratory study using cells made from one patient (hiPSCs) and shaped toward kidney-like cells, a novel BBS7 missense change was tied to lower levels of BBS7 and BBS2 proteins, shorter and abnormal cilia, and less organized nephron-like structures. The same work reported reduced activity of a signaling pathway important for development (the SHH pathway) and proposed that the mutation could expose the protein to degradation through MARCHF1. [3]

What this may mean for patients and caregivers

These studies may matter later because they strengthen the genetic and biological map of BBS, including newly reported variants and specific ideas about how they can disrupt cilia-related processes. For patients and families pursuing genetic answers, this type of work supports why finding the exact gene change can be informative, even when day-to-day care is not immediately altered by a lab mechanism study. [2] [3]

Important uncertainty remains because one report focused on a single family and the other used kidney-like cells from a single patient in the lab. That means the proposed mechanisms need confirmation in more people and additional experiments before they can be treated as settled explanations for kidney or other BBS features. [2] [3]

What changed this month

This month, case reports highlighted two practical realities for families affected by suspected BBS: symptoms can differ even among siblings with the same BBS gene change, and some people who look like they have BBS early on may actually have a different genetic condition. Together, these reports reinforce the value of careful follow-up over time and broad genetic testing when the full picture is not yet clear. [4] [5]

In one family, four siblings all had the same pathogenic MKKS (also called BBS6) variant, yet their kidney and liver findings differed across family members despite shared core features like early obesity, retinal dystrophy, and extra fingers or toes. This shows that even with the same genetic cause, BBS can look different within one household. [4]

In another report, an infant with severe early vision problems and postaxial polydactyly was initially considered to have BBS, but over 6 years no other BBS features emerged. Whole-exome sequencing later supported two separate diagnoses instead: CEP290-related LCA10 (an inherited retinal disease) plus a GLI3 variant explaining isolated polydactyly. [5]

What this may mean for patients and caregivers

These case reports matter mainly as learning examples: they help set expectations that BBS features can vary widely, and they show why the diagnosis can sometimes change as new symptoms appear or do not appear. This does not establish new rules for diagnosis, but it supports the idea that genetic results and long-term observation can be important when the early signs overlap with other conditions. [4] [5]

What remains uncertain is how often situations like these occur, because each report includes only one family or one person. Still, the shared message is straightforward: a BBS-like starting presentation does not always mean BBS, and even confirmed BBS can differ from one person to the next. [4] [5]